“High-dose” UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides - 02/09/11
Abstract |
Background: UVA1 (340 to 400 nm) was found to be effective in the treatment of early-stage mycosis fungoides (MF). Objective: The purpose of this study was to assess the efficacy of UVA1 phototherapy for widespread plaque-type, nodular, and erythrodermic MF. Methods: Thirteen patients (8 with stage IB, 4 with IIB, and 1 with III MF) received 100 J/cm2 UVA1 daily until remission. Four patients also had lesions inaccessible by UVA1 that were considered control lesions. Immunocytologic studies of skin infiltrates and circulating T cells were done before and after the therapy. Results: Eleven patients showed complete clinical and histologic responses. Two patients had a partial improvement. Unirradiated control lesions never improved. Serious short-term side effects were not recorded. Circulating CD4+/CD45RO+ and CD4+/CD95+ lymphocytes were significantly reduced by the therapy. Conclusion: UVA1 therapy is an effective and well-tolerated treatment for advanced MF. The therapeutic relevance of the effects on circulating lymphocytes remains to be established because lesions in nonexposed cutaneous areas did not respond.
Le texte complet de cet article est disponible en PDF.Plan
Reprint requests: Cristina Zane, MD, Department of Dermatology, Azienda Spedali Civili, P.le Spedali Civili 1,25123 Brescia, Italy. |
|
J Am Acad Dermatol 2001;44:629-33 |
Vol 44 - N° 4
P. 629-633 - avril 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?